PROMISE: Our kitties will never sit on top of content. Please turn off your ad blocker for our site.
puuuuuuurrrrrrrrrrrr
Michael Causey
Published: Thursday, November 21, 2013 - 17:24 A new Food and Drug Administration (FDA) draft guidance, “Medical Device Development Tools—Draft Guidance for Industry, Tool Developers, and Food and Drug Administration Staff,” outlines a voluntary process for qualification of medical device development tools (MDDT).
The guidance, issued Nov. 14, 2013, by the Center for Devices and Radiological Health (CDRH), is designed to facilitate the development and “timely evaluation of innovative” medical devices; it describes the framework and process of voluntary CDRH qualification of MDDT. An MDDT is a scientifically validated tool—such as a clinical outcome assessment or a test to detect or measure a biomarker—designed to aid device development and regulatory evaluation. The guidance also includes helpful definitions of key concepts that provide something of a window into FDA’s viewpoint and regulatory expectations. Here are two important examples of how FDA views the world: According to the guidance, CDRH is developing a qualification process because it provides a mechanism for leveraging advances in regulatory science, encouraging MDDT development and adoption, and “facilitating faster, more efficient device development and regulatory evaluation.” However, the guidance intentionally stays away from any specific evidentiary or performance expectations the agency would have for qualifying a specific MDDT. The FDA is accepting comments and suggestions for revising the guidance until early February 2014. Electronic comments should be sent to www.regulations.gov. First published Nov. 19, 2013, on the AssurX blog. Quality Digest does not charge readers for its content. We believe that industry news is important for you to do your job, and Quality Digest supports businesses of all types. However, someone has to pay for this content. And that’s where advertising comes in. Most people consider ads a nuisance, but they do serve a useful function besides allowing media companies to stay afloat. They keep you aware of new products and services relevant to your industry. All ads in Quality Digest apply directly to products and services that most of our readers need. You won’t see automobile or health supplement ads. So please consider turning off your ad blocker for our site. Thanks, James Michael Causey’s been a journalist since he started his own neighborhood newspaper in the 1970s. In addition to quizzing FDA officials for the past 10+ years, he’s also interviewed political satirist Art Buchwald, FCC Chairman Reed Hundt, SEC Chairwoman Mary Schapiro, and is the past president of the Washington Independent Writers. Causey is the editor and publisher of eDataIntegrityReport.com and is a contributing writer on the AssurXblog.FDA Accepting Comments on ‘Medical Device Development Tools’
Guidance describes framework and process of voluntary CDRH qualification
• Qualification: A conclusion that within a specified “context of use,” CDRH expects that the results of an assessment that uses MDDT can be relied upon to support device development and regulatory decision making.
• Context of use: “Use” is defined, in part, by the device or product area for which the MDDT is qualified, the stage of device development, and the specific role of the MDDT.
Our PROMISE: Quality Digest only displays static ads that never overlay or cover up content. They never get in your way. They are there for you to read, or not.
Quality Digest Discuss
About The Author
Michael Causey
© 2023 Quality Digest. Copyright on content held by Quality Digest or by individual authors. Contact Quality Digest for reprint information.
“Quality Digest" is a trademark owned by Quality Circle Institute, Inc.